Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: A project of Kyushu University liver disease study

Norihiro Furusyo, Hiroaki Takeoka, Kazuhiro Toyoda, Masayuki Murata, Yuichi Tanabe, Eiji Kajiwara, Junya Shimono, Akihide Masumoto, Toshihiro Maruyama, Hideyuki Nomura, Makoto Nakamuta, Kazuhiro Takahashi, Shinji Shimoda, Koichi Azuma, Hironori Sakai, Jun Hayashi, H. Nakashima, N. Kubo, Y. Yokota, T. KugaA. Mitsutake, H. Ohnishi, S. Maeda, Y. Nakagawa, R. Sugimoto, H. Amagase, S. Tominaga, K. Yanagita, K. Ogawara, M. Tokumatsu, S. Tabata, M. Yokota, H. Tanaka, S. Nagase, S. Tsuruta, S. Tada, M. Nagano, M. Honda, T. Umeno, T. Sugimura, S. Ueno, S. Miki, H. Okubo, H. Fujimoto, N. Higuchi, S. Shigematsu, N. Higashi

研究成果: ジャーナルへの寄稿記事

11 引用 (Scopus)

抄録

Aim: To determine the efficacy of long-term lamivudine treatment of a large number of Japanese patients with chronic hepatitis B. Methods: In this retrospective, multi-center trial, 318 Japanese patients with chronic hepatitis B received 100 mg of lamivudine daily for up to 36 (median 21) mo. Virological response was a decline to a serum HBV DNA level less than 3.7 log copies/mL. Virological breakthrough was defined as the reappearance of a serum HBV DNA level to more than 10-fold the minimum during treatment. Results: Lamivudine produced virological response in 86.8% of the 318 patients at 6 mo, in 80.2% of 252 patients at 12 mo, in 69.2% of 133 patients at 24 mo, and in 53.6% of 28 patients at 36 mo. Forward stepwise logistic regression analysis showed an HBV DNA level less than 6.8 log copies/mL (P<0.0001), HBeAg negativity (P<0.0001), a platelet count of 100 × 109/L or more (P=0.0162) at baseline, and a decline of the HBV DNA level of more than 3.2 log copies/mL as compared with the baseline level at 3 mo after the start of treatment (P=0.0003) to be significantly associated with virological response. Among patients with a virological response, virological breakthrough was seen in 5.3% of 19 patients who responded virologically at 1 mo, in 20.7% of 203 patients at 3 mo, in 27.5% of 51 patients at 6 mo, in 33.3% of 12 patients at 9 mo, and in 100% of 3 patients at ≥15 mo. A virological breakthrough was found significantly more often in patients with delayed virological response. Conclusion: Lamivudine treatment could suppress serum HBV DNA in most of the tested Japanese patients. Long-term efficacy might be seen in patients without HBeAg at baseline, in the absence of cirrhosis, and in patients with a decline in HBV DNA level soon after the start of treatment.

元の言語英語
ページ(範囲)561-567
ページ数7
ジャーナルWorld Journal of Gastroenterology
12
発行部数4
DOI
出版物ステータス出版済み - 1 28 2006

Fingerprint

Lamivudine
Chronic Hepatitis B
Liver Diseases
Therapeutics
DNA
Hepatitis B e Antigens
Serum
Platelet Count

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

Long-term lamivudine treatment for chronic hepatitis B in Japanese patients : A project of Kyushu University liver disease study. / Furusyo, Norihiro; Takeoka, Hiroaki; Toyoda, Kazuhiro; Murata, Masayuki; Tanabe, Yuichi; Kajiwara, Eiji; Shimono, Junya; Masumoto, Akihide; Maruyama, Toshihiro; Nomura, Hideyuki; Nakamuta, Makoto; Takahashi, Kazuhiro; Shimoda, Shinji; Azuma, Koichi; Sakai, Hironori; Hayashi, Jun; Nakashima, H.; Kubo, N.; Yokota, Y.; Kuga, T.; Mitsutake, A.; Ohnishi, H.; Maeda, S.; Nakagawa, Y.; Sugimoto, R.; Amagase, H.; Tominaga, S.; Yanagita, K.; Ogawara, K.; Tokumatsu, M.; Tabata, S.; Yokota, M.; Tanaka, H.; Nagase, S.; Tsuruta, S.; Tada, S.; Nagano, M.; Honda, M.; Umeno, T.; Sugimura, T.; Ueno, S.; Miki, S.; Okubo, H.; Fujimoto, H.; Higuchi, N.; Shigematsu, S.; Higashi, N.

:: World Journal of Gastroenterology, 巻 12, 番号 4, 28.01.2006, p. 561-567.

研究成果: ジャーナルへの寄稿記事

Furusyo, N, Takeoka, H, Toyoda, K, Murata, M, Tanabe, Y, Kajiwara, E, Shimono, J, Masumoto, A, Maruyama, T, Nomura, H, Nakamuta, M, Takahashi, K, Shimoda, S, Azuma, K, Sakai, H, Hayashi, J, Nakashima, H, Kubo, N, Yokota, Y, Kuga, T, Mitsutake, A, Ohnishi, H, Maeda, S, Nakagawa, Y, Sugimoto, R, Amagase, H, Tominaga, S, Yanagita, K, Ogawara, K, Tokumatsu, M, Tabata, S, Yokota, M, Tanaka, H, Nagase, S, Tsuruta, S, Tada, S, Nagano, M, Honda, M, Umeno, T, Sugimura, T, Ueno, S, Miki, S, Okubo, H, Fujimoto, H, Higuchi, N, Shigematsu, S & Higashi, N 2006, 'Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: A project of Kyushu University liver disease study', World Journal of Gastroenterology, 巻. 12, 番号 4, pp. 561-567. https://doi.org/10.3748/wjg.v12.i4.561
Furusyo, Norihiro ; Takeoka, Hiroaki ; Toyoda, Kazuhiro ; Murata, Masayuki ; Tanabe, Yuichi ; Kajiwara, Eiji ; Shimono, Junya ; Masumoto, Akihide ; Maruyama, Toshihiro ; Nomura, Hideyuki ; Nakamuta, Makoto ; Takahashi, Kazuhiro ; Shimoda, Shinji ; Azuma, Koichi ; Sakai, Hironori ; Hayashi, Jun ; Nakashima, H. ; Kubo, N. ; Yokota, Y. ; Kuga, T. ; Mitsutake, A. ; Ohnishi, H. ; Maeda, S. ; Nakagawa, Y. ; Sugimoto, R. ; Amagase, H. ; Tominaga, S. ; Yanagita, K. ; Ogawara, K. ; Tokumatsu, M. ; Tabata, S. ; Yokota, M. ; Tanaka, H. ; Nagase, S. ; Tsuruta, S. ; Tada, S. ; Nagano, M. ; Honda, M. ; Umeno, T. ; Sugimura, T. ; Ueno, S. ; Miki, S. ; Okubo, H. ; Fujimoto, H. ; Higuchi, N. ; Shigematsu, S. ; Higashi, N. / Long-term lamivudine treatment for chronic hepatitis B in Japanese patients : A project of Kyushu University liver disease study. :: World Journal of Gastroenterology. 2006 ; 巻 12, 番号 4. pp. 561-567.
@article{415c5dafbf9a4dfe9c48d5f772062007,
title = "Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: A project of Kyushu University liver disease study",
abstract = "Aim: To determine the efficacy of long-term lamivudine treatment of a large number of Japanese patients with chronic hepatitis B. Methods: In this retrospective, multi-center trial, 318 Japanese patients with chronic hepatitis B received 100 mg of lamivudine daily for up to 36 (median 21) mo. Virological response was a decline to a serum HBV DNA level less than 3.7 log copies/mL. Virological breakthrough was defined as the reappearance of a serum HBV DNA level to more than 10-fold the minimum during treatment. Results: Lamivudine produced virological response in 86.8{\%} of the 318 patients at 6 mo, in 80.2{\%} of 252 patients at 12 mo, in 69.2{\%} of 133 patients at 24 mo, and in 53.6{\%} of 28 patients at 36 mo. Forward stepwise logistic regression analysis showed an HBV DNA level less than 6.8 log copies/mL (P<0.0001), HBeAg negativity (P<0.0001), a platelet count of 100 × 109/L or more (P=0.0162) at baseline, and a decline of the HBV DNA level of more than 3.2 log copies/mL as compared with the baseline level at 3 mo after the start of treatment (P=0.0003) to be significantly associated with virological response. Among patients with a virological response, virological breakthrough was seen in 5.3{\%} of 19 patients who responded virologically at 1 mo, in 20.7{\%} of 203 patients at 3 mo, in 27.5{\%} of 51 patients at 6 mo, in 33.3{\%} of 12 patients at 9 mo, and in 100{\%} of 3 patients at ≥15 mo. A virological breakthrough was found significantly more often in patients with delayed virological response. Conclusion: Lamivudine treatment could suppress serum HBV DNA in most of the tested Japanese patients. Long-term efficacy might be seen in patients without HBeAg at baseline, in the absence of cirrhosis, and in patients with a decline in HBV DNA level soon after the start of treatment.",
author = "Norihiro Furusyo and Hiroaki Takeoka and Kazuhiro Toyoda and Masayuki Murata and Yuichi Tanabe and Eiji Kajiwara and Junya Shimono and Akihide Masumoto and Toshihiro Maruyama and Hideyuki Nomura and Makoto Nakamuta and Kazuhiro Takahashi and Shinji Shimoda and Koichi Azuma and Hironori Sakai and Jun Hayashi and H. Nakashima and N. Kubo and Y. Yokota and T. Kuga and A. Mitsutake and H. Ohnishi and S. Maeda and Y. Nakagawa and R. Sugimoto and H. Amagase and S. Tominaga and K. Yanagita and K. Ogawara and M. Tokumatsu and S. Tabata and M. Yokota and H. Tanaka and S. Nagase and S. Tsuruta and S. Tada and M. Nagano and M. Honda and T. Umeno and T. Sugimura and S. Ueno and S. Miki and H. Okubo and H. Fujimoto and N. Higuchi and S. Shigematsu and N. Higashi",
year = "2006",
month = "1",
day = "28",
doi = "10.3748/wjg.v12.i4.561",
language = "English",
volume = "12",
pages = "561--567",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "4",

}

TY - JOUR

T1 - Long-term lamivudine treatment for chronic hepatitis B in Japanese patients

T2 - A project of Kyushu University liver disease study

AU - Furusyo, Norihiro

AU - Takeoka, Hiroaki

AU - Toyoda, Kazuhiro

AU - Murata, Masayuki

AU - Tanabe, Yuichi

AU - Kajiwara, Eiji

AU - Shimono, Junya

AU - Masumoto, Akihide

AU - Maruyama, Toshihiro

AU - Nomura, Hideyuki

AU - Nakamuta, Makoto

AU - Takahashi, Kazuhiro

AU - Shimoda, Shinji

AU - Azuma, Koichi

AU - Sakai, Hironori

AU - Hayashi, Jun

AU - Nakashima, H.

AU - Kubo, N.

AU - Yokota, Y.

AU - Kuga, T.

AU - Mitsutake, A.

AU - Ohnishi, H.

AU - Maeda, S.

AU - Nakagawa, Y.

AU - Sugimoto, R.

AU - Amagase, H.

AU - Tominaga, S.

AU - Yanagita, K.

AU - Ogawara, K.

AU - Tokumatsu, M.

AU - Tabata, S.

AU - Yokota, M.

AU - Tanaka, H.

AU - Nagase, S.

AU - Tsuruta, S.

AU - Tada, S.

AU - Nagano, M.

AU - Honda, M.

AU - Umeno, T.

AU - Sugimura, T.

AU - Ueno, S.

AU - Miki, S.

AU - Okubo, H.

AU - Fujimoto, H.

AU - Higuchi, N.

AU - Shigematsu, S.

AU - Higashi, N.

PY - 2006/1/28

Y1 - 2006/1/28

N2 - Aim: To determine the efficacy of long-term lamivudine treatment of a large number of Japanese patients with chronic hepatitis B. Methods: In this retrospective, multi-center trial, 318 Japanese patients with chronic hepatitis B received 100 mg of lamivudine daily for up to 36 (median 21) mo. Virological response was a decline to a serum HBV DNA level less than 3.7 log copies/mL. Virological breakthrough was defined as the reappearance of a serum HBV DNA level to more than 10-fold the minimum during treatment. Results: Lamivudine produced virological response in 86.8% of the 318 patients at 6 mo, in 80.2% of 252 patients at 12 mo, in 69.2% of 133 patients at 24 mo, and in 53.6% of 28 patients at 36 mo. Forward stepwise logistic regression analysis showed an HBV DNA level less than 6.8 log copies/mL (P<0.0001), HBeAg negativity (P<0.0001), a platelet count of 100 × 109/L or more (P=0.0162) at baseline, and a decline of the HBV DNA level of more than 3.2 log copies/mL as compared with the baseline level at 3 mo after the start of treatment (P=0.0003) to be significantly associated with virological response. Among patients with a virological response, virological breakthrough was seen in 5.3% of 19 patients who responded virologically at 1 mo, in 20.7% of 203 patients at 3 mo, in 27.5% of 51 patients at 6 mo, in 33.3% of 12 patients at 9 mo, and in 100% of 3 patients at ≥15 mo. A virological breakthrough was found significantly more often in patients with delayed virological response. Conclusion: Lamivudine treatment could suppress serum HBV DNA in most of the tested Japanese patients. Long-term efficacy might be seen in patients without HBeAg at baseline, in the absence of cirrhosis, and in patients with a decline in HBV DNA level soon after the start of treatment.

AB - Aim: To determine the efficacy of long-term lamivudine treatment of a large number of Japanese patients with chronic hepatitis B. Methods: In this retrospective, multi-center trial, 318 Japanese patients with chronic hepatitis B received 100 mg of lamivudine daily for up to 36 (median 21) mo. Virological response was a decline to a serum HBV DNA level less than 3.7 log copies/mL. Virological breakthrough was defined as the reappearance of a serum HBV DNA level to more than 10-fold the minimum during treatment. Results: Lamivudine produced virological response in 86.8% of the 318 patients at 6 mo, in 80.2% of 252 patients at 12 mo, in 69.2% of 133 patients at 24 mo, and in 53.6% of 28 patients at 36 mo. Forward stepwise logistic regression analysis showed an HBV DNA level less than 6.8 log copies/mL (P<0.0001), HBeAg negativity (P<0.0001), a platelet count of 100 × 109/L or more (P=0.0162) at baseline, and a decline of the HBV DNA level of more than 3.2 log copies/mL as compared with the baseline level at 3 mo after the start of treatment (P=0.0003) to be significantly associated with virological response. Among patients with a virological response, virological breakthrough was seen in 5.3% of 19 patients who responded virologically at 1 mo, in 20.7% of 203 patients at 3 mo, in 27.5% of 51 patients at 6 mo, in 33.3% of 12 patients at 9 mo, and in 100% of 3 patients at ≥15 mo. A virological breakthrough was found significantly more often in patients with delayed virological response. Conclusion: Lamivudine treatment could suppress serum HBV DNA in most of the tested Japanese patients. Long-term efficacy might be seen in patients without HBeAg at baseline, in the absence of cirrhosis, and in patients with a decline in HBV DNA level soon after the start of treatment.

UR - http://www.scopus.com/inward/record.url?scp=33644883330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644883330&partnerID=8YFLogxK

U2 - 10.3748/wjg.v12.i4.561

DO - 10.3748/wjg.v12.i4.561

M3 - Article

C2 - 16489669

AN - SCOPUS:33644883330

VL - 12

SP - 561

EP - 567

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 4

ER -